Nektar Therapeutics (NKTR) Misses Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $74.80 -0.13%
EPS Growth %: +26.6%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
CRMT, PKE, HELE, More
EPS Growth %: +26.6%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $37.5 million versus the consensus estimate of $40.85 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
- Rivian offers Q2 2026 revenue outlook, cash position grows
- UBS Reiterates Neutral Rating on Carter's (CRI)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
